Top

Published in:

01-01-2014 | Research Article

Identification of genes and candidate agents associated with pancreatic cancer

Authors: Bao-sheng Wang, Zhen Liu, Shao-long Sun, Yi Zhao

Published in: Tumor Biology | Issue 1/2014

Abstract

Pancreatic cancer is a malignant neoplasm originating from transformed cells arising in tissues forming the pancreas. A major challenge in current cancer research is biological interpretation of complexity of cancer somatic mutation profiles. It has been suggested that several molecular alterations may play important roles in pancreatic carcinogenesis. In this study, by using the GSE28735 affymetrix microarray data accessible from Gene Expression Omnibus (GEO) database, we identified differentially expressed genes (DEGs) between paired pancreatic cancer tissues and adjacent nontumor tissues, followed the protein–protein interaction of the DEGs. Our study identified thousands of DEGs involved in regulation of cell cycle and apoptosis in progression of pancreatic cancer. Sp1 was predicted to be the major regulator by transcription factors analysis. From the protein–protein interaction networks, we found that Tk1 might play an important role in the progression of pancreatic cancer. Finally, we predicted candidate agents, including tomatidine and nialamide, which may be used as drugs to treat pancreatic cancer. In conclusion, our data provide a comprehensive bioinformatics analysis of genes and pathways which may be involved in the progression of pancreatic cancer.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. doi:10.3322/caac.20073.PubMedCrossRef

Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049–57. doi:10.1016/S0140-6736(04)15841-8S0140-6736(04)15841-8.PubMedCrossRef

Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther. 2006;5(4):787–96. doi:10.1158/1535-7163.MCT-06-0005.PubMedCrossRef

Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20(2):211–26. doi:10.1016/j.bpg.2005.10.002.PubMedCrossRef

Mimeault M, Brand RE, Sasson AA, Batra SK. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas. 2005;31(4):301–16.PubMedCrossRef

Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol. 2005;23(20):4524–31. doi:10.1200/JCO.2005.19.711.PubMedCrossRef

Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology. 2009;150(9):3991–4002. doi:10.1210/en.2009-0573.PubMedCrossRef

Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, et al. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLoS One. 2012;7(2):e31507. doi:10.1371/journal.pone.0031507PONE-D-11-21687.PubMedCentralPubMedCrossRef

Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249–64. doi:10.1093/biostatistics/4.2.2494/2/249.PubMedCrossRef

10.

Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98(9):5116–21. doi:10.1073/pnas.091062498091062498.PubMedCrossRef

11.

Benjamini YH Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodol). 1995;57:289–300.

12.

Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P, Kim JS, et al. A novel signaling pathway impact analysis. Bioinformatics. 2009;25(1):75–82. doi:10.1093/bioinformatics/btn577btn577.PubMedCrossRef

13.

Roider HG, Manke T, O'Keeffe S, Vingron M, Haas SA. PASTAA: identifying transcription factors associated with sets of co-regulated genes. Bioinformatics. 2009;25(4):435–42. doi:10.1093/bioinformatics/btn627btn627.PubMedCrossRef

14.

Roider HG, Kanhere A, Manke T, Vingron M. Predicting transcription factor affinities to DNA from a biophysical model. Bioinformatics. 2007;23(2):134–41. doi:10.1093/bioinformatics/btl565.PubMedCrossRef

15.

Das J, Yu H. HINT: High-quality protein interactomes and their applications in understanding human disease. BMC Syst Biol. 2012;6:92. doi:10.1186/1752-0509-6-92.PubMedCentralPubMedCrossRef

16.

Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929–35. doi:10.1126/science.1132939.PubMedCrossRef

17.

Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford). 2008;10(1):58–62. doi:10.1080/13651820701883148.CrossRef

18.

Tan M, Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol. 2007;608:119–29.PubMedCrossRef

19.

Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005;192(3):813–8. doi:10.1016/j.ajog.2004.10.605.PubMedCrossRef

20.

Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53(4):549–54.PubMedCrossRef

21.

Collins MA, Brisset JC, Zhang Y, Bednar F, Pierre J, Heist KA, et al. Metastatic pancreatic cancer is dependent on oncogenic kras in mice. PLoS One. 2012;7(12):e49707. doi:10.1371/journal.pone.0049707PONE-D-12-09212.PubMedCentralPubMedCrossRef

22.

Hruban RH, Adsay NV. Molecular classification of neoplasms of the pancreas. Hum Pathol. 2009;40(5):612–23. doi:10.1016/j.humpath.2009.01.008.PubMedCrossRef

23.

Dergham ST, Dugan MC, Sarkar FH, Vaitkevicius VK. Molecular alterations associated with improved survival in pancreatic cancer patients treated with radiation or chemotherapy. J Hepatobiliary Pancreat Surg. 1998;5(3):269–72.PubMedCrossRef

24.

Hezel AF, Deshpande V, Zimmerman SM, Contino G, Alagesan B, O'Dell MR, et al. TGF-beta and alphavbeta6 integrin act in a common pathway to suppress pancreatic cancer progression. Cancer Res. 2012;72(18):4840–5. doi:10.1158/0008-5472.CAN-12-06340008-5472.CAN-12-0634.PubMedCentralPubMedCrossRef

25.

Hahn SA, Hoque AT, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E, et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res. 1996;56(3):490–4.PubMed

26.

Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 2010;70(12):4972–81. doi:10.1158/0008-5472.CAN-09-3573.PubMedCentralPubMedCrossRef

27.

Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res. 2011;17(11):3706–15. doi:10.1158/1078-0432.CCR-10-3082.PubMedCentralPubMedCrossRef

28.

Vance S, Liu E, Zhao L, Parsels JD, Parsels LA, Brown JL, et al. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle. 2011;10(24):4321–9. doi:10.4161/cc.10.24.1866118661.PubMedCrossRef

29.

Rajkumar T, Soumittra N, Nancy NK, Swaminathan R, Sridevi V, Shanta V. BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India. Asian Pac J Cancer Prev. 2003;4(3):203–8.PubMed

30.

Antoniou A, Pharoah P, Narod S, Risch HA, Eyfjord JE, Hopper J, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117.PubMedCentralPubMedCrossRef

31.

Greer JB, Whitcomb DC. Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut. 2007;56(5):601–5. doi:10.1136/gut.2006.101220.PubMedCrossRef

32.

Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2012;107(12):2005–9. doi:10.1038/bjc.2012.483bjc2012483.PubMedCentralPubMedCrossRef

33.

Liu R, Zhou A, Ren D, He A, Hu X, Zhang W, et al. Transcription factor specificity protein 1 (SP1) and activating protein 2alpha (AP-2alpha) regulate expression of human KCTD10 gene by binding to proximal region of promoter. FEBS J. 2009;276(4):1114–24. doi:10.1111/j.1742-4658.2008.06855.x.PubMedCrossRef

34.

Li B, Wang X, Zhou F, Saunders NA, Frazer IH, Zhao KN. Up-regulated expression of Sp1 protein coincident with a viral protein in human and mouse differentiating keratinocytes may act as a cell differentiation marker. Differentiation. 2008;76(10):1068–80. doi:10.1111/j.1432-0436.2008.00300.x.PubMedCrossRef

35.

Nichols AF, Itoh T, Zolezzi F, Hutsell S, Linn S. Basal transcriptional regulation of human damage-specific DNA-binding protein genes DDB1 and DDB2 by Sp1, E2F, N-myc and NF1 elements. Nucleic Acids Res. 2003;31(2):562–9.PubMedCentralPubMedCrossRef

36.

Yuan P, Wang L, Wei D, Zhang J, Jia Z, Li Q, et al. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer. 2007;110(12):2682–90. doi:10.1002/cncr.23092.PubMedCrossRef

37.

Won J, Yim J, Kim TK. Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells. J Biol Chem. 2002;277(41):38230–8. doi:10.1074/jbc.M206064200.PubMedCrossRef

38.

Tang S, Bhatia B, Zhou J, Maldonado CJ, Chandra D, Kim E, et al. Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells. Oncogene. 2004;23(41):6942–53. doi:10.1038/sj.onc.1207913.PubMedCrossRef

39.

Lin SY, Black AR, Kostic D, Pajovic S, Hoover CN, Azizkhan JC. Cell cycle-regulated association of E2F1 and Sp1 is related to their functional interaction. Mol Cell Biol. 1996;16(4):1668–75.PubMedCentralPubMed

40.

Jungert K, Buck A, von Wichert G, Adler G, König A, Buchholz M, et al. Sp1 is required for transforming growth factor-β-induced mesenchymal transition and migration in pancreatic cancer cells. Cancer Res. 2007;67(4):1563–70.PubMedCrossRef

41.

Rotheneder H, Geymayer S, Haidweger E. Transcription factors of the Sp1 family: interaction with E2F and regulation of the murine thymidine kinase promoter. J Mol Biol. 1999;293(5):1005–15. doi:10.1006/jmbi.1999.3213.PubMedCrossRef

42.

Karlseder J, Rotheneder H, Wintersberger E. Interaction of Sp1 with the growth- and cell cycle-regulated transcription factor E2F. Mol Cell Biol. 1996;16(4):1659–67.PubMedCentralPubMed

43.

Jia Z, Gao Y, Wang L, Li Q, Zhang J, Le X, et al. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res. 2010;70(3):1111–9. doi:10.1158/0008-5472.CAN-09-3282.PubMedCentralPubMedCrossRef

44.

Jutooru I, Chadalapaka G, Lei P, Safe S. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem. 2010;285(33):25332–44. doi:10.1074/jbc.M109.095240.PubMedCrossRef

45.

Jenal M, Trinh E, Britschgi C, Britschgi A, Roh V, Vorburger SA, et al. The tumor suppressor gene hypermethylated in cancer 1 is transcriptionally regulated by E2F1. Mol Cancer Res. 2009;7(6):916–22. doi:10.1158/1541-7786.MCR-08-0359.PubMedCrossRef

46.

Shaw J, Yurkova N, Zhang T, Gang H, Aguilar F, Weidman D, et al. Antagonism of E2F-1 regulated Bnip3 transcription by NF-kappaB is essential for basal cell survival. Proc Natl Acad Sci USA. 2008;105(52):20734–9. doi:10.1073/pnas.0807735105.PubMedCrossRef

47.

Xu Y, Shi QL, Ma H, Zhou H, Lu Z, Yu B, et al. High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma. Tumour Biol. 2012;33(2):475–83. doi:10.1007/s13277-011-0276-0.PubMedCrossRef

48.

Prochazka V, Faber E, Raida L, Langova K, Indrak K, Papajik T. High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma. Leuk Lymphoma. 2012;53(7):1306–10. doi:10.3109/10428194.2011.654339.PubMedCrossRef

Title: Identification of genes and candidate agents associated with pancreatic cancer
Authors: Bao-sheng Wang
Zhen Liu
Shao-long Sun
Yi Zhao
Publication date: 01-01-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 1/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1009-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

SMAD4 is a potential prognostic marker in human breast carcinomas

TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma

Quantitative assessment of the association between TP53 Arg72Pro polymorphism and risk of glioma

Association between vestibular schwannomas and mobile phone use

Association of Kaposi’s sarcoma-associated herpesvirus (KSHV) with bladder cancer in Croatian patients

Association of rs2233678 and rs2233679 polymorphisms in the PIN1 gene with cancer risk: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer